Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2025-05-15 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV announcing that new clinical trial data for their CAR-T candidate GLPG5101 has been accepted for oral presentation at upcoming medical conferences (EHA and ICML 2025). It provides a summary of the results to be presented, details on the study (ATALANTA-1), and contact information. This is a standard corporate announcement regarding research and development progress, which falls under the category of Regulatory Filings (RNS) as it is a general corporate announcement that does not fit into more specific categories like earnings releases or financial reports.
2025-05-15 English
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV announcing upcoming oral presentations of clinical trial data (ATALANTA-1 study) at medical conferences (EHA and ICML). It provides details on the study, the drug candidate GLPG5101, and the nature of the data to be presented. It does not constitute a formal financial report, earnings release, or regulatory filing, but rather a corporate announcement regarding scientific progress. As it does not fit into specific categories like 10-K, ER, or CT, it falls under the general regulatory announcement category.
2025-05-15 English
6-K Filing
Regulatory Filings
2025-05-14 English
Galapagos kondigt een strategische update aan over de geplande splitsing, de transitie van het uitvoerend leiderschap, en wijzigingen in de Raad van Bestuur
Board/Management Information Classification · 98% confidence The document is a press release from Galapagos NV announcing significant changes in corporate strategy (re-evaluating a planned spin-off) and leadership (appointment of a new CEO and Chairman). While it contains management changes, the primary focus is on a major strategic shift and business development update. According to the filing definitions, announcements regarding board and management changes fall under 'MANG'. Although it also touches on strategy, 'MANG' is the most specific category for the leadership transition announcements which are the core of the document's headline and content.
2025-05-13 English
Galapagos kondigt een strategische update aan over de geplande splitsing, de transitie van het uitvoerend leiderschap, en wijzigingen in de Raad van Bestuur
Board/Management Information Classification · 95% confidence The document is a press release from Galapagos NV announcing significant changes to its executive leadership (new CEO) and Board of Directors (new Chair), as well as a strategic update regarding a previously announced corporate separation. While it touches on strategic alternatives, the primary and most immediate content is the announcement of management and board transitions. According to the filing definitions, announcements of changes in the board of directors or senior management fall under the 'MANG' category.
2025-05-13 English
GLPG Press-release Strategic Review May 2025 ENG.pdf
Board/Management Information Classification · 99% confidence The document is a press release titled "Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes." It details significant corporate actions, including the re-evaluation of a proposed separation, the appointment of a new CEO (Mr. Henry Gosebruch), and changes to the Board Chair. This content directly relates to changes in senior management and the board of directors. This aligns perfectly with the definition for Board/Management Information (MANG). While it mentions the Annual Report on Form 20-F in the forward-looking statements section, the primary purpose and content of this specific document is the announcement of leadership and strategic changes, not the filing of the full annual report itself.
2025-05-13 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.